Compare IMUX & ALIS Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IMUX | ALIS |
|---|---|---|
| Founded | 2016 | 2024 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | |
| Sector | Health Care | |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 85.8M | 83.9M |
| IPO Year | N/A | 2025 |
| Metric | IMUX | ALIS |
|---|---|---|
| Price | $0.66 | $9.98 |
| Analyst Decision | Strong Buy | |
| Analyst Count | 5 | 0 |
| Target Price | ★ $6.00 | N/A |
| AVG Volume (30 Days) | ★ 1.7M | 43.3K |
| Earning Date | 02-14-2026 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | N/A |
| EPS | N/A | ★ N/A |
| Revenue | N/A | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | N/A | N/A |
| Revenue Growth | N/A | N/A |
| 52 Week Low | $0.51 | $9.85 |
| 52 Week High | $1.39 | $9.97 |
| Indicator | IMUX | ALIS |
|---|---|---|
| Relative Strength Index (RSI) | 53.31 | N/A |
| Support Level | $0.64 | N/A |
| Resistance Level | $0.71 | N/A |
| Average True Range (ATR) | 0.05 | 0.00 |
| MACD | 0.01 | 0.00 |
| Stochastic Oscillator | 71.90 | 0.00 |
Immunic Inc is a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies aimed at treating chronic inflammatory and autoimmune diseases, including ulcerative colitis, Crohn's disease, relapsing-remitting multiple sclerosis, and psoriasis. The company is developing small molecule products, which include IMU-838, which is a selective immune modulator that inhibits the intracellular metabolism of activated immune cells by blocking the enzyme DHODH; IMU-935 is an inverse agonist of RORyt, and IMU-856 targets the restoration of the intestinal barrier function.
Calisa Acquisition Corp is a blank check company with the purpose of effecting a merger, asset acquisition, stock exchange, stock purchase, reorganization, or similar business combination.